Inverness Medical Innovations

Alere President and CEO Ron Zwanziger last week provided investors with an update on the development timeline for a pair of point-of-care nucleic acid testing plartforms, the company's first molecular diagnostics products.

Health management-services and diagnostics firm Alere is developing a pair of nucleic acid testing platforms, representing the company's first major move into the molecular diagnostics space, according to recent company presentations.

In clinical studies, the test demonstrated 97.1 percent positive agreement and 100 percent negative agreement with conventional methods of testing for MRSA, AdvanDx said.

Inverness will sell the real-time PCR assay in Germany, Austria, and Switzerland.

The UK-based company also signed on Inverness Medical Canada to distribute its products in the country.

Inverness, through its Biosite division, will develop and evaluate tests using Miraculins' panel of 35 biomarkers for placenta development and preeclampsia.

In an SEC filing, Thermo Fisher said that it believes the termination results from its recent decision to expand its diagnostics portfolio. Among Biosite's products are protein-based tests for congestive heart failure and cardiovascular diseases.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.